Have a take on $IRWD? Post an insight below.
Stock Price: $4.39 • 11/9/26
Ironwood Pharmaceuticals (IRWD) sells gastrointestinal medicines, sharing U.S. profits from constipation treatment LINZESS with AbbVie.
November 5 results showed quarterly reported profit rose 49% to $59.8 million, as prescription demand grew and costs fell. Ironwood raised its sales outlook and repaid $60 million of debt. Expanding sites for its short-bowel disease trial and January's leadership handover offer coming-weeks developments to watch.
With a market cap of approximately $727 million, IRWD trades at approximately 3x annualized latest-quarter reported profit, or 3.6x annualized nine-month profit. That pace may not last: generic competition, rising trial costs, dependence on AbbVie and dilution threaten earnings. Debt of $325 million exceeds $86 million cash, and shares already rallied 16% over November 4-6.
Opinion: IRWD appears potentially undervalued if growing LINZESS demand sustains cash flow while trial expansion advances despite generic competition and development risks.
Daily closes 路 through Nov 06, 2026 路 Yahoo Finance
Share what the market may be missing. No account needed. 0 insights below.
Recent insights from readers. Verify claims before acting on them.
Be the first to share an insight on this stock.